NCT06361238RecruitingPhase 3
Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery
Perioperative Application of Liraglutide for the Prevention of Postoperative Delirium Among Elderly Patients with Type 2 Diabetes Undergoing Cardiac Surgery: a Single-Center Randomized Controlled Study
Source: ClinicalTrials.gov · Last updated 20 Dec 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to clarify the preventive effect of perioperative liraglutide application on postoperative delirium in elderly patients with Type 2 diabetes undergoing cardiac surgery.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- First submitted
- 19 Mar 2024
- Start date
- 19 Nov 2024
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Diseases
- Type 2 diabetes
- NCT number
- NCT06361238
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 260
- From 19 Nov 2024 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous use of GLP-1A and SGLT2i
Other illness
- History of neurological or psychiatric disorders, such as schizophrenia, epilepsy, Parkinson's disease, severe dementia, etc
- History of central nervous system damage or surgery
- Cardiac function NYHA Class IV
- Severe renal failure requiring renal replacement therapy
- History of pancreatitis
- Type 1 diabetes
- Patients with medullary thyroid carcinoma or a family history of it
- Intolerance or allergy to liraglutide
Lab values
- Patients whose blood sugar is difficult to control within 4-8 mmol/L during the screening period
Other
- Patients with communication difficulties, such as severe visual, auditory, or speech impairments
- Severe liver dysfunction (Child-Pugh Class C)
- Pregnant or breastfeeding women
- Patients who refuse to sign the informed consent
Who the study is looking for
- Age ≥ 60 years
- Type 2 diabetes
- Patients undergoing elective cardiac surgery
Age in the registry: 60 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wenxue liu Coordinator of this site? Confirm its status | Nanjing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.